Table 3

Description of included assessment methods

Assessment methodsValidated?Description
Investigator Global Assessment-Atopic Dermatitis (IGA)Partially20Static 6-point scale based on assessment of erythema and infiltration/papulation from 0 (clear) to 5 (very severe disease)

In most trials, scores ≤1 were generally classified as “treatment success,” whereas scores >1 were considered “treatment failure.”
0-clearNo inflammatory signs of disease
1-almost clearJust perceptible erythema and infiltration/papulation
2-mild diseaseMild erythema and infiltration/papulation
3-moderate diseaseModerate erythema and infiltration/papulation
4-severe diseaseSevere erythema and infiltration/papulation
5-very severe diseaseSevere erythema and infiltration/papulation with oozing/crusting
Physician Global Evaluation (PGE)UnknownChange in clinical status scored as percent improvement of lesions identified for treatment at baseline.

Typically, “success” was defined as ≥ 90% improvement of the monitored lesions.
90% to 99%Excellent improvement
75% to 89%Marked improvement
50% to 74%Moderate improvement
30% to 49%Slight improvement
0% to 29%No improvement
Eczema Area and Severity Index (EASI)21Yes204-point (0, none; 1, mild; 2, moderate; 3, severe) scale assessing erythema, infiltration/papulation, excoriation, and lichenification separately on the head/neck, trunk, upper limbs, and lower limbs.

EASI assigns proportionate values to each of the 4 body regions (roughly based on the “rule of nines”). The overall score ranges from 0 (no disease) to 72 (all signs of disease rated severe and present on 100% of body surface area).
Body regionsScoring formulaa
Upper limbs(Eryth+Infil+Excor+Lich) × area involved × 0.2
Lower limbs(Eryth+Infil+Excor+Lich) × area involved × 0.4
Trunk(Eryth+Infil+Excor+Lich) × area involved × 0.3
Head/neck(Eryth+Infil+Excor+Lich) × area involved × 0.1
aarea involved within each body region was estimated as the percentage of the total area of that region.

From: Methods

Cover of Drug Class Review: Topical Calcineurin Inhibitors
Drug Class Review: Topical Calcineurin Inhibitors: Final Report [Internet].
Lee NJ, McDonagh M, Chan B, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.